Form 4: Revolution Medicines Director Receives Equity Compensation Grant

Revolution Medicines, Inc. Director Flavia Borellini reported the acquisition of 3,142 restricted stock units and 11,574 stock options on June 26, 2025, as part of her compensation.

Summary

• Director Flavia Borellini acquired 3,142 shares of Common Stock at a price of $0.
• Following this transaction, Flavia Borellini beneficially owns 25,024 shares of Common Stock, which includes the 3,142 Restricted Stock Units.
• Flavia Borellini also acquired 11,574 stock options with an exercise price of $37.48.
• These stock options expire on June 26, 2035.
• The 11,574 shares subject to the option will vest on the earlier of the first anniversary of June 26, 2025, or immediately prior to the Annual Meeting following the grant date, contingent on her remaining a Service Provider.

Sentiment

Score: 6

Explanation: The filing indicates routine equity compensation for a director, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. No significant positive or negative financial news is conveyed.

Positives

• The grant of equity to a director aligns their interests with shareholders, potentially encouraging long-term value creation.

Future Outlook

N/A

Industry Context

This Form 4 filing reflects routine equity compensation for a director in the biotechnology or pharmaceutical industry, common for aligning executive and board interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with shareholders, potentially encouraging long-term value creation.

Next Steps

• The stock options are subject to vesting conditions, including remaining a Service Provider through the vesting date.

Key Dates

Keywords

Revolution Medicines, RVMD, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Flavia Borellini